158776-75-1

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(2,3-Dimethoxy-benzyl)-piperazine is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. Its unique structure allows for the development of new drugs with potentially improved efficacy and reduced side effects.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(2,3-Dimethoxy-benzyl)-piperazine is used as a building block for designing and developing novel therapeutic agents. Its interactions with biological targets make it a promising candidate for creating drugs that can target specific diseases or conditions.
Used in Drug Development:
1-(2,3-Dimethoxy-benzyl)-piperazine is also utilized in drug development to create new compounds with potential therapeutic effects. Its ability to modify the activity of biological targets can lead to the discovery of new treatments for various medical conditions.
Caution:
As with any chemical compound, 1-(2,3-Dimethoxy-benzyl)-piperazine should be handled and used with caution. It may have toxic or harmful effects if not properly managed, and its safety profile should be thoroughly evaluated before use in any pharmaceutical or medicinal application.

Upstream product

• 86-51-1 2,3-dimethyoxybenzaldehyde 
• 415924-58-2 4-(2,3-dimethoxy-benzyl)-piperazine-1-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Design, synthesis and SAR of antitubercular benzylpiperazine ureas

Abstract: N-furfuryl piperazine ureas disclosed by scientists at GSK Tres Cantos were chosen as antimycobacterial hits from a phenotypic whole-cell screen. Bioisosteric replacement of the furan ring in the GSK Tres Cantos molecules with a phenyl ring led to molecule (I) with an MIC of 1?μM against Mtb H37Rv, low cellular toxicity (HepG2 IC50 ~ 80?μM), good DMPK properties and specificity for Mtb. With the aim of delineating the SAR associated with (I), fifty-five analogs were synthesized and screened against Mtb. The SAR suggests that the piperazine ring, benzyl urea and piperonyl moieties are essential signatures of this series. Active compounds in this series are metabolically stable, have low cellular toxicity and are valuable leads for optimization. Molecular docking suggests these molecules occupy the Q0 site of QcrB like Q203. Graphic Abstract: Bioisosteric replacement of N-furfuryl piperazine-1-carboxamides yielded molecule (I) a novel lead with satisfactory PD, metabolism, and toxicity profiles.[Figure not available: see fulltext.]

Flavonoid-related modulators of multidrug resistance: Synthesis, pharmacological activity, and structure-activity relationships

A series of 28 flavonoid derivatives containing a N-benzylpiperazine chain have been synthesized and tested for their ability to modulate multidrug resistance (MDR) in vitro. At 5 μM, most compounds potentiated doxorubicin cytotoxicity on resistant K562/DOX cells. They were also able to increase the intracellular accumulation of JC-1, a fluorescent molecule recently described as a probe of P-glycoprotein-mediated MDR. This suggests that these compounds act, at least in part, by inhibiting P-glycoprotein activity. As in other studies, lipophilicity was shown to influence MDR- modulating activity but was not the only determinant. Diverse di- and trimethoxy substitutions on N-benzyl were examined and found to affect the activity differently. The most active compounds had a 2,3,4- trimethoxybenzylpiperazine chain attached to either a flavone or a flavanone moiety (13, 19, 33, and 37) and were found to be more potent than verapamil.